ped - I think once a IRB at the site has approval to use imetelstat to treat MF then it is easier and faster to add trials for other indications. Plus logistical components already in place.
hi mangy - yes all good. John heads back to Mayo Monday for 3 week infusion. They keep adding sites and that means they keep adding patients so I am guessing lots of Johns out there. And the strength of current trials could be foundation for all future trials as Scarlett alluded or maybe news at AACR or something else? By the way, angry and negative board posts are inversely proportionate to potential for positive news IMO.
taz - yes. This talk of 2nd line therapy is the latest misinformation. The trial was designed as 2nd line therapy to prove better than Jakafi to get BAT designation IMO. BAT is one of the 3 FDA criteria for pre-approval distribution as part of registry study in lieu of phase 3 under ODD designation. Not to mention - does anyone really think a dying patient with no time to lose is going to agree to first "try" any drug proven palliative only with severe side effects - like jakafi, hydroxurea, interferon - and wait patiently to start imetelstat with proven clinical benefit in almost everyone and PR and CR in some and relatively mild side effects (severe ones managed with dosing). Based on my experience, I am confident imetelstat is on track for 1st line therapy because it will prove to be the only real treatment as opposed to temporary symptom amelioration. If you were a patient, what would you demand?
Hi big - ligas is a shill and that is why he is hated by patients. Imetelstat will be frontline therapy. Who is going to require dying patients to take any palliative drug (like ligas said on MF FB page) such as jakafi, hydroxurea, or interferon that are proven not to work and with severe side effects as soon as imetelstat is available with clinical benefit, PR, CR with relatively and manageable (long term) side effects? No wonder they tossed that poser off the board. Wish we could toss a few off here. Regardless, they will be gone soon enough. As Dr. Scarlett said, 2016 could be a very good year for Geron.